

MYELOMA TRIALS OPEN TO RECRUITMENT AT CCC-L

DISEASE	Front Line or Relapsed/Refractory	Key entry criteria	Trial name & Treatment
Myeloma		Group 1: Newly diagnosed MM, Eligible for ASCT Group 2: Newly diagnosed OR current MM Ineligible for ASCT Group 3: Newly diagnosed OR current SMM	BLOOM (Observational) Improving the monitoring and treatment of multiple myeloma patients by comparing cellular and serological markers of minimal residual disease
	Front line	Newly diagnosed Multiple Myeloma (MM) - Not eligible for stem cell transplant	FiTNEss (Myeloma XIV) Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma: A phase III trial to compare standard and frailty-adjusted induction therapy with ixazomib, lenalidomide and dexamethasone (IRD) and maintenance lenalidomide (R) to lenalidomide plus ixazomib (R+I)
		- Newly diagnosed with multiple myeloma - Must not be eligible for transplant - Will be treated with a first-line lenalidomide-containing or nonlenalidomide-containing regimen	NDMM PASS MM034 A prospective non-interventional post-authorization safety study (PASS) of lenalidomide in previously untreated adult multiple myeloma patients who are not eligible for transplant
	Relapsed /Refractory		
Determine the role of ixazomib as an Augmented Conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT Consolidation and maintenance strategy in patients with Relapsed multiple myeloma (ACCoRd)		ACCoRD (Myeloma XII) Phase 3 trial 4-6 cycles ITD to at least SD then randomized to either ASCT-con + Melphalan or ASCT-aug + Melphalan and Ixazomib Maintenance no further treatment or 2 cycles ITD and Ixazomib until DP	

MYELOMA TRIALS OPEN TO RECRUITMENT AT CCC-L

		≥ 2 lines of therapy including proteasome inhibitor and Lenalidomide that Cyclophosphamide and prednisolone would be appropriate	MUK 12 Phase II randomized trial of Selinexor, Cyclo and Pred v's Cyclo Pred with crossover if required
--	--	--	---